Hansoh Pharmaceutical Group Co. Ltd.

09/24/2026 | Press release | Distributed by Public on 09/24/2026 11:33

翰森制药 | 瑞康立伏妥塔单抗治疗骨肉瘤上市许可申请获国家药品监督管理局受理

[ [1] 第二批罕见病目录.国家卫健委，国卫医政发[2023]26号，2023年9月18日.

[2] Durfee RA, Mohammed M, Luu HH. Review of Osteosarcoma and Current Management. Rheumatol Ther. 2016 Dec;3(2):221-243. DOI: 10.1007/s40744-016-0046-y.

[3] Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021;385(22):2066-2076.

[4] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Bone Cancer. August 20, 2024. Version 1.2025. Accessed October 24, 2024. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf

[5] Chinese Society of Clinical Oncology (CSCO). CSCO Clinical Practice Guidelines: Bone and Soft Tissue Cancer (2024).

Hansoh Pharmaceutical Group Co. Ltd. published this content on September 24, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 24, 2026 at 17:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]